SCHEMBL488739

SCHEMBL488739

OCc1cccc(F)c1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 4/20 0.41
P2RX7 Q99572 1/20 0.40
SLC6A4 P31645 2/20 0.39
CYP2D6 P10635 1/20 0.39
SLC6A2 P23975 1/20 0.39
KCNH2 Q12809 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.36
TIPARP Q7Z3E1 1/20 0.35
PTGS2 P35354 1/20 0.35
CMA1 P23946 3/20 0.34
TAAR1 Q96RJ0 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16951797 0.87 PDK2 (0.42) PDK2SIRT2TIPARPAPOBEC3GLMNA
SCHEMBL27630340 0.84 SLC6A4 (0.40) PDK2P2RX7SLC6A4CYP2D6SLC6A2
SCHEMBL17414710 0.82 TAAR1 (0.37) PDK2CYP2D6TAAR1APOBEC3GMEN1
SCHEMBL25535141 0.82 RIPK1 (0.36) PDK2P2RX7CYP2D6TAAR1APOBEC3G
SCHEMBL16959012 0.79 TSHR (0.39) PDK2CYP2D6SIRT2TIPARPTAAR1
SCHEMBL542693 0.79 IDO1 (0.41) PDK2SIRT2TIPARPPTGS2APOBEC3G
SCHEMBL30368290 0.79 IDO1 (0.41) PDK2SIRT2TIPARPPTGS2APOBEC3G
SCHEMBL7230776 0.79 P2RX7 (0.40) P2RX7SLC6A4CYP2D6SLC6A2KCNH2
SCHEMBL19356887 0.79 SLC6A4 (0.39) PDK2P2RX7SLC6A4CYP2D6SLC6A2
SCHEMBL16701725 0.79 SLC6A4 (0.39) PDK2P2RX7SLC6A4CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6544974-B2 Treating atherosclerosis and other coronary artery diseases. G.D. SEARLE & CO. 2003-04-08 US claimed
EP-4484407-A2 (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE NIKON CORPORATION (JP) 2025-01-01 EP disclosed
CN-116082563-B (Meth) acrylate compound, optical resin additive, optical element, and optical device 株式会社 尼康 2024-09-20 CN disclosed
CN-118359760-A Optical resin, optical element, and optical device 株式会社 尼康 2024-07-19 CN disclosed
CN-116082563-A (meth) acrylate compound, optical resin additive, optical element, and optical device 株式会社 尼康 2023-05-09 CN disclosed
US-11142636-B2 (Meth)acrylate compound, additive for optical resin, optical element, and optical device NIKON CORPORATION (JP) 2021-10-12 US disclosed
US-20190322857-A1 (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE NIKON CORPORATION (JP) 2019-10-24 US disclosed
CN-110088077-A (meth) acrylate compound, optical resin additive, optical element, and optical device 株式会社尼康 2019-08-02 CN disclosed
CN-103265477-B Aminoheteroaryl compounds as protein kinase inhibitors 苏根公司 2017-01-11 CN disclosed
EP-1603570-B9 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN INC (US) 2013-10-23 EP disclosed
EP-1603570-B1 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN INC (US) 2013-01-23 EP disclosed
EP-2476667-A2 Aminoheteroaryl compounds as protein kinase inhibitors Sugen, Inc. (US) 2012-07-18 EP disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed
CN-1777427-A Aminoheteroaryl compounds as protein kinase inhibitors SUGEN INC (US) 2006-05-24 CN disclosed
EP-1603570-A2 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2005-12-14 EP disclosed
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. 2005-01-13 US disclosed
WO-2004076412-A2 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer MET, ERBB2, CDK4 PDK2 371/4885P2RX7 2802/4885SLC6A4 4263/4885
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 PDK2 533/4885P2RX7 4386/4885SLC6A4 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.